Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.
The effects of SR-49059, a new nonpeptide and selective arginine vasopressin (AVP) V1a antagonist, were investigated in binding and functional studies on cultured human aortic vascular smooth muscle cells (VSMC). Characterization of human vascular V1a receptors, using a specific V1a radioiodinated ligand, showed that [125I]-linear AVP antagonist binding to human VSMC membranes was time dependent, reversible, and saturable. A single population of high-affinity binding sites (apparent equilibrium dissociation constant = 15 +/- 6 pM; maximum binding density = 36 +/- 5 fmol/mg protein, i.e., approximately 3,000 sites/cell) with the expected V1a profile was identified. Exposure of these cells to AVP dose-dependently produced cytosolic free [Ca2+] increase [AVP concentration required to obtain a half-maximal response (EC50) = 23 +/- 9 nM] and proliferation (EC50 = 3.2 +/- 0.5 nM). SR-49059 strongly and stereospecifically inhibited [125I]-linear AVP antagonist binding to VSMC V1a receptors [inhibition constant (Ki) = 1.4 +/- 0.3 nM], AVP-evoked Ca2+ increase [concentration of inhibitor required to obtain 50% inhibition of specific binding (IC50) = 0.41 +/- 0.06 nM], and the mitogenic effects induced by 100 nM AVP (IC50 = 0.83 +/- 0.04 nM). OPC-21268, another nonpeptide V1a antagonist, was more than two orders of magnitude less potent than SR-49059 in these models. However, the consistent affinity (Ki = 138 +/- 21 nM) and activity found with OPC-21268 on human VSMC in comparison with the inactivity already observed for other human V1a receptors (liver, platelets, adrenals, and uterus) strongly suggested the existence of human AVP V1a-receptor subtypes.(ABSTRACT TRUNCATED AT 250 WORDS)
Sanofi Recherche, Toulouse, France.
C
C
Serradeil-Le Gal
J M
JM
Herbert
C
C
Delisee
P
P
Schaeffer
D
D
Raufaste
C
C
Garcia
F
F
Dol
E
E
Marty
J P
JP
Maffrand
G
G
Le Fur
D001011:Aorta / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D001127:Arginine Vasopressin / Q000494:pharmacology*; D002118:Calcium / Q000378:metabolism*; D002455:Cell Division / Q000187:drug effects; D002462:Cell Membrane / Q000378:metabolism; D002478:Cells, Cultured; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D007457:Iodine Radioisotopes; D007700:Kinetics; D009131:Muscle, Smooth, Vascular / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D010121:Oxytocin / Q000494:pharmacology; D010880:Piperidines / Q000378:metabolism; D011759:Pyrrolidines / Q000494:pharmacology*; D015363:Quinolones / Q000378:metabolism; D011869:Radioligand Assay; D017483:Receptors, Vasopressin / Q000378:metabolism*; D014667:Vasopressins / Q000819:agonists / Q000037:antagonists & inhibitors*
D007211:Indoles; D007457:Iodine Radioisotopes; D010880:Piperidines; D011759:Pyrrolidines; D015363:Quinolones; D017483:Receptors, Vasopressin; D014667:Vasopressins; D001127:Arginine Vasopressin; C068644:OPC 21268; D010121:Oxytocin; C082134:relcovaptan; D003894:Deamino Arginine Vasopressin; D002118:Calcium